Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

NCT04676386 is registered in ClinicalTrials.gov with Addario Lung Cancer Medical Institute as lead sponsor.

NCT NCT04676386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy
Lead sponsor
Addario Lung Cancer Medical Institute
Phase
Observational
Overall status
Terminated
Start date
February 1, 2021
Completion date
December 30, 2023
Enrollment
29 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv, nsclc, stage iiic